Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT stu
In a recent issue of The Lancet, CHDS visiting scholar Tone Enden has investigated treatment of additional catheter-directed thrombolysis (CDT) as compared to the standard treatment for deep vein thrombosis (DVT). Dr. Enden, a cardiologist at the Oslo University Hospital, implemented a randomized controlled trial that was the first to evaluate the efficacy of CDT. A significant reduction in risk was associated with additional CDT when compared to standard treatment, albeit with a small increase in the risk of bleeding. Based on these findings, the investigators concluded that treatment should be considered for patients with DVT who had a low risk of bleeding. This study has the potential to contribute towards needed changes to treatment guidelines for DVT.